Literature DB >> 22661052

Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab.

Emilio Besada1, Johannes C Nossent.   

Abstract

We report a 63-year-old man with large-vessel giant cell arteritis with affection of the aorta in its thoracal descendens and abdominal segments, both axillar arteries and the left carotid artery. The diagnosis was confirmed with positive biopsy of the temporal artery. The patient was treated with prednisolone at first and thereafter with methotrexate. Due to a moderate clinical response, tocilizumab at a dose of 8 mg/kg was added 8 weeks after diagnosis. The patient did not improve clinically, and the prednisolone dose could not be tapered rapidly as previously reported in small case series. Nevertheless, the wall oedema determined by ultrasonography in both axillar and left carotid arteries almost disappeared 2 months after tocilizumab initiation. Two months after the last tocilizumab, the patient relapsed clinically. Tocilizumab seems to be an effective therapy with faster resolution of the vessel wall oedema determined by ultrasonography by suppressing Th17-cell activity. But the clinical improvement in our patient has been moderate and short-lived due to persistent Th1 cells activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22661052     DOI: 10.1007/s10067-012-2007-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  11 in total

1.  Prognosis of large-vessel giant cell arteritis.

Authors:  W A Schmidt; A Moll; A Seifert; B Schicke; E Gromnica-Ihle; A Krause
Journal:  Rheumatology (Oxford)       Date:  2008-07-14       Impact factor: 7.580

2.  Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis.

Authors:  Christian Beyer; Roland Axmann; Enijad Sahinbegovic; Jörg H Distler; Bernhard Manger; Georg Schett; Jochen Zwerina
Journal:  Ann Rheum Dis       Date:  2011-04-24       Impact factor: 19.103

Review 3.  IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis.

Authors:  Cornelia M Weyand; Brian R Younge; Jörg J Goronzy
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

4.  Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series.

Authors:  Michael Seitz; Stephan Reichenbach; Harald M Bonel; Sabine Adler; Felix Wermelinger; Peter M Villiger
Journal:  Swiss Med Wkly       Date:  2011-01-17       Impact factor: 2.193

5.  Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.

Authors:  J A Jover; C Hernández-García; I C Morado; E Vargas; A Bañares; B Fernández-Gutiérrez
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

Review 6.  Imaging for large-vessel vasculitis.

Authors:  Daniel Blockmans; Thorsten Bley; Wolfgang Schmidt
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

7.  Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.

Authors:  Gary S Hoffman; Maria C Cid; Karen E Rendt-Zagar; Peter A Merkel; Cornelia M Weyand; John H Stone; Carlo Salvarani; Weichun Xu; Sudha Visvanathan; Mahboob U Rahman
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

8.  Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.

Authors:  Norihiro Nishimoto; Hideko Nakahara; Naoko Yoshio-Hoshino; Toru Mima
Journal:  Arthritis Rheum       Date:  2008-04

9.  Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.

Authors:  N E Roche; J W Fulbright; A D Wagner; G G Hunder; J J Goronzy; C M Weyand
Journal:  Arthritis Rheum       Date:  1993-09

10.  A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.

Authors:  V M Martínez-Taboada; V Rodríguez-Valverde; L Carreño; J López-Longo; M Figueroa; J Belzunegui; E M Mola; G Bonilla
Journal:  Ann Rheum Dis       Date:  2007-12-17       Impact factor: 19.103

View more
  4 in total

Review 1.  Biologic Therapy for the Treatment of Giant Cell Arteritis.

Authors:  Rochella A Ostrowski; Melissa R Bussey; Rodney Tehrani; Walter Jay
Journal:  Neuroophthalmology       Date:  2014-04-02

Review 2.  Update on the management of giant cell arteritis.

Authors:  Janet Roberts; Alison Clifford
Journal:  Ther Adv Chronic Dis       Date:  2017-03-28       Impact factor: 5.091

Review 3.  Tocilizumab: a new therapy for large vessel vasculitis.

Authors:  Ibrahim A Al-Homood
Journal:  Clin Exp Med       Date:  2013-08-15       Impact factor: 3.984

4.  Design of the tocilizumab in giant cell arteritis trial.

Authors:  Sebastian H Unizony; Bhaskar Dasgupta; Elena Fisheleva; Lucy Rowell; Georg Schett; Robert Spiera; Jochen Zwerina; Olivier Harari; John H Stone
Journal:  Int J Rheumatol       Date:  2013-04-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.